CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 33 enrolled
Drug / intervention
ZD1839 in combination with docetaxeldrug
Likely dose
ZD1839 in combination with docetaxel 75 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00052169
NCT00052169Phase 2Completed
CompareCT.gov

A Phase 2, Multi-Center Trial of ZD1839 (IRESSA) in Combination With Docetaxel as First-Line Treatment in Patients With Advanced Breast Cancer

NSABP Foundation Inc·interventional·Posted Jan 27, 2003·Updated Dec 18, 2007

In Brief

A Phase 2 clinical trial evaluating ZD1839 in combination with docetaxel for Breast Neoplasms. Completed, enrolled 33 participants across 1 site.

Detailed Summary

The purpose of this study is to learn how breast cancer tumors respond to treatment combining the drugs docetaxel and ZD1839.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Neoplasms
CountriesUnited States
CollaboratorsAstraZeneca

Timeline

Phase 2CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 27, 2003
Enrollment StartJan 1, 2003
Study CompletionSep 1, 2006
TodayJul 1, 2026
Posted 23.4 years ago

Interventions

ZD1839 in combination with docetaxeldrug

Docetaxel given as 75 mg/m2 IV every 3 weeks combined with ZD1839 (IRESSA) 250 mg orally daily until disease progression or withdrawal criteria are met.